Piao, M., Li, C., Li, S., Zhang, N., Li, J., Luo, X., Liu, R., Wang, F., Shi, X., Liu, C., Tan, G., Zhu, Z., Yang, X., Zhao, H.

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study

10 de February de 2026 by Piao, M., Li, C., Li, S., Zhang, N., Li, J., Luo, X., Liu, R., Wang, F., Shi, X., Liu, C., Tan, G., Zhu, Z., Yang, X., Zhao, H.

Background
Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitors combined with chemotherapy have improved patient outcomes, their toxicity remains concerning. …